免疫血栓形成及其潜在的生物机制
Arthur Cunha De Nardi1, Andréa Coy-Canguçu1, Atena Saito1
1Pontifícia Universidade Católica de Campinas (PUCC), Faculdade de Medicina, Campinas, Brazil.
Hematology, transfusion and cell therapy
|July 14, 2023
概括
血液凝固 (凝血) 和免疫之间的联系在放松调节时可以导致有害的血栓形成,这种过程称为免疫血栓形成. 了解免疫血栓形成是开发用于COVID-19等疾病的新疗法的关键.
科学领域:
- * 免疫血栓研究桥梁血液学,免疫学和传染病.
- * 专注于凝血与先天免疫之间的进化联系.
背景情况:
- *免疫和凝血之间的生理相互作用有助于病原体防御.
- *放松血液静止和免疫力导致病理性免疫血栓形成.
- *免疫血栓形成是包括COVID-19在内的血栓性疾病的基础.
研究的目的:
- * 审查免疫血栓形成的分子和细胞机制.
- *强调中性粒细胞外细胞陷 (NETs),血小板和凝血的作用.
- * 检查血液静止放松如何恶化COVID-19等疾病.
主要方法:
- *关于免疫血栓形成的综合文献综述.
- *分析涉及NETs,血小板和凝固的分子途径.
- *使用COVID-19作为临床模型的案例研究方法.
主要成果:
- * 极端炎症会改变凝血和免疫细胞功能,增加凝结能力.
- * 免疫血栓形成涉及NET,血小板和凝血级联等关键参与者.
- *放松血静可显著加剧患有血栓性疾病的患者情况.
结论:
- *了解免疫血栓形成对于开发有效疗法至关重要.
- *针对免疫血栓形成的机制可以预防和治疗COVID-19和其他疾病中的血栓形成.
- * 需要进一步研究血液静止和免疫相互作用,以改善患者的治疗结果.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Disorders of Hemostasis
999
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
999
Venous Thrombosis I: Introduction
13
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
13
Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


